New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
06:39 EDTICPTIntercept trial deaths unlikely associated with treatment, says Wedbush
Wedush believes the two deaths that occurred during the FLINT Phase 2b trial disclosed late Friday by Intercept are unlikely related to the OCA treatment. The firm says any continued weakness in shares of Intercept would be a buying opportunity and keeps an Outperform rating on the name with a $493 price target.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
09:15 EDTICPTIntercept recent weakness a buying opportunity, says Summer Street
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use